Ferroptosis-centered Drug Response Information

General Information of the Drug (ID: ferrodrug0196)
Name
Polydatin
Synonyms
Piceid; 27208-80-6; 65914-17-2; Trans-Piceid; 3,4,5-Trihydroxystilbene-3-beta-monoglucoside; 3,4,5-Tsg; (2S,3R,4S,5S,6R)-2-(3-Hydroxy-5-(4-hydroxystyryl)phenoxy)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol; Resveratrol 3-beta-mono-D-glucoside; (2S,3R,4S,5S,6R)-2-[3-hydroxy-5-[(E)-2-(4-hydroxyphenyl)ethenyl]phenoxy]-6-(hydroxymethyl)oxane-3,4,5-triol; Resveratrol 3-O-beta-glucopyranoside; (E/Z)-Piceid; MLS001424114; CHEBI:8198; XM261C37CQ; (2S,3R,4S,5S,6R)-2-(3-hydroxy-5-((E)-4-hydroxystyryl)phenoxy)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol; trans-resveratrol 3-beta-glucoside; trans-resveratrol 3-beta-D-glucoside; 3,4'-5-Trihydroxystilbene-3-beta-D-glucopyranoside; trans-resveratrol 3-O-beta-D-glucoside; 3,5,4'-Trihydroxystilbene 3-glucoside; SMR000466371; 3,4',5-trihydroxystilbene-3-beta-D-glucoside; b-D-Glucopyranoside,3-hydroxy-5-[(1E)-2-(4-hydroxyphenyl)ethenyl]phenyl; C20H22O8; Resveratrol 3-Glucoside; 5-Tsg; resveratrol 3-O-beta-D-glucoside; UNII-XM261C37CQ; MFCD00210592; E/Z-Polydatin; E/Z-Piceid; (E)-Piceid; 5-Trihydroxystilbene-3-beta-monoglucoside; 3-Hydroxy-5-(2-(4-hydroxyphenyl)ethenyl)phenyl-beta-D-glucoside; Resveratrol 3-O-glucoside; Resveratrol 5-O-glucoside; SCHEMBL41411; MLS000759499; trans-Resveratrol 3-glucoside; CHEMBL142652; Resveratrol 3-beta-D-glucoside; trans-Resveratrol 3-O-glucoside; BDBM60919; CHEBI:94610; cid_5281718; HSTZMXCBWJGKHG-CUYWLFDKSA-N; DTXSID001030555; HMS2051A20; HY-N0120; resveratrol-3-O-b-mono-D-glucoside; LMPK13090012; s2390; AKOS015961013; CCG-100895; DB11263; KS-5384; NC00145; Resveratrol 3-.beta.-mono-d-glucoside; NCGC00246971-01; NCGC00246971-04; (2S,3R,4S,5S,6R)-2-[3-hydroxy-5-[(E)-2-(4-hydroxyphenyl)vinyl]phenoxy]-6-(hydroxymethyl)tetrahydropyran-3,4,5-triol; AS-13910; trans-resveratrol 3-beta-d-glucopyranoside; CS-0007830; AB00639953-07; EN300-7416763; 3,4',5-Trihydroxystilbene-3-b-D-glucopyranoside; A818955; 5,4'-dihydroxystilbene-3-O-beta-D-glucopyranoside; Q-100342; Q3902665; RESVERATROL 3-.BETA.-MONO-D-GLUCOSIDE [MI]; W-203441; 3,4',5-TRIHYDROXYSTILBENE-3-BETA-MONOGLUCOSIDE; 3,4'-5-Trihydroxystilbene-3-beta-D-glucopyranoside, 97%; 3,4'-5-TRIHYDROXYSTILBENE-3-.BETA.-D-GLUCOPYRANOSIDE; 3-Hydroxy-5-[(1E)-2-(4-hydroxyphenyl)ethenyl]phenyl-beta-D-glucopyranoside; 3-hydroxy-5-[(E)-2-(4-hydroxyphenyl)ethenyl]phenyl beta-D-glucopyranoside; 3-Hydroxy-5-[2-(4-hydroxyphenyl)ethenyl]phenyl beta-D-glucopyranoside; b-D-Glucopyranoside, 3-hydroxy-5-[2-(4-hydroxyphenyl)ethenyl]phenyl; beta-D-Glucopyranoside, 3-hydroxy-5-(2-(4-hydroxyphenyl)ethenyl)phenyl; GLUCOPYRANOSIDE, 3-HYDROXY-5-(P-HYDROXYSTYRYL)PHENYL, .BETA.-D-; .BETA.-D-GLUCOPYRANOSIDE, 3-HYDROXY-5-((1E)-2-(4-HYDROXYPHENYL)ETHENYL)PHENYL; .BETA.-D-GLUCOPYRANOSIDE, 3-HYDROXY-5-(2-(4-HYDROXYPHENYL)ETHENYL)PHENYL; 5-((1E)-2-(4-HYDROXYPHENYL)ETHENYL)-1,3-BENZENEDIOL-3-.BETA.-MONO-D-GLUCOSIDE; beta-D-Glucopyranoside, 3-hydroxy-5-(2-(4-hydroxyphenyl)ethenyl)phenyl-, (E)-; (2R,3S,4S,5R,6S)-2-(hydroxymethyl)-6-[3-[(E)-2-(4-hydroxyphenyl)ethenyl]-5-oxidanyl-phenoxy]oxane-3,4,5-triol; (2S,3R,4S,5S,6R)-2-[3-hydroxy-5-[(E)-2-(4-hydroxyphenyl)vinyl]phenoxy]-6-methylol-tetrahydropyran-3,4,5-triol; (2S,3R,4S,5S,6R)-2-{3-hydroxy-5-[(1E)-2-(4-hydroxyphenyl)ethenyl]phenoxy}-6-(hydroxymethyl)oxane-3,4,5-triol; .beta.-D-Glucopyranoside, 3-hydroxy-5-[(1E)-2-(4-hydroxyphenyl)ethenyl]phenyl3,5,4'-Trihydroxystilbene 3-glucoside

    Click to Show/Hide
Structure
Formula
C20H22O8
IUPAC Name
(2S,3R,4S,5S,6R)-2-[3-hydroxy-5-[(E)-2-(4-hydroxyphenyl)ethenyl]phenoxy]-6-(hydroxymethyl)oxane-3,4,5-triol
Canonical SMILES
C1=CC(=CC=C1C=CC2=CC(=CC(=C2)OC3C(C(C(C(O3)CO)O)O)O)O)O
InChI
InChI=1S/C20H22O8/c21-10-16-17(24)18(25)19(26)20(28-16)27-15-8-12(7-14(23)9-15)2-1-11-3-5-13(22)6-4-11/h1-9,16-26H,10H2/b2-1+/t16-,17-,18+,19-,20-/m1/s1
InChIKey
HSTZMXCBWJGKHG-CUYWLFDKSA-N
PubChem CID
5281718
Full List of Ferroptosis Target Related to This Drug
Phospholipid hydroperoxide glutathione peroxidase (GPX4)
 Target Info 
In total 1 item(s) under this Target
Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target [1]
Target for Ferroptosis Suppressor
Responsed Disease Acute kidney failure ICD-11: GB60
 Disease Info 
Pathway Response Fatty acid metabolism hsa01212
Ferroptosis hsa04216
Cell Process Cell ferroptosis
In Vitro Model HK-2 cells Normal Homo sapiens CVCL_0302
In Vivo Model
Male C57BL/6 mice (8-10 weeks of age, weight 20-25 g) were purchased from Experimental Animal Center of the Fourth Military Medical University (Xi'an, China) and bred in an experimental animal room of SPF grade. They were randomly divided into four groups: control (equivalent saline containing 1% DMSO) group (n = 5), cisplatin (20 mg/kg dissolved in saline) only group (n = 7), cisplatin + polydatin (40 mg/kg dissolved in 1% DMSO) group (n = 7), and cisplatin+ Fer-1 (5 mg/kg dissolved in 1% DMSO) group (n = 7) were administered intraperitoneally. Mice were injected with cisplatin once; PD or Fer-1 was given 1 h before and 24 h after cisplatin. Animals were ethically sacrificed by dislocating their spines at 48 h after cisplatin injection, and whole blood and kidneys were collected for further analysis.

    Click to Show/Hide
Response regulation In vitro and in vivo experiments indicated the prominent nephroprotective effects of polydatin against ferroptosis in cisplatin-induced acute kidney injury models, occurred at least partly through inhibiting excessive intracellular free iron accumulation and ROS production, rescuing GSH consumption, and enhancing GPx4 activity, thereby decreasing lipid peroxidation and ferroptosis sensitivity and ultimately attenuating the pathological progression of AKI.
References
Ref 1 Polydatin Attenuates Cisplatin-Induced Acute Kidney Injury by Inhibiting Ferroptosis. Oxid Med Cell Longev. 2022 Jan 15;2022:9947191. doi: 10.1155/2022/9947191. eCollection 2022.